Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
40.6M
-
Number of holders
-
3
-
Total 13F shares, excl. options
-
49.8K
-
Shares change
-
-35K
-
Total reported value, excl. options
-
$1.99M
-
Value change
-
-$1.39M
-
Number of buys
-
1
-
Number of sells
-
-1
-
Price
-
$39.76
Significant Holders of Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) as of Q4 2023
3 filings reported holding KROS - Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q4 2023.
Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) has 3 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 49.8K shares
of 40.6M outstanding shares and own 0.12% of the company stock.
Largest 10 shareholders include FMR LLC (3.87M shares), BlackRock Inc. (2.04M shares), ALKEON CAPITAL MANAGEMENT LLC (1.5M shares), VANGUARD GROUP INC (1.43M shares), ORBIMED ADVISORS LLC (1.27M shares), BRAIDWELL LP (1.12M shares), Darwin Global Management, Ltd. (1.06M shares), STATE STREET CORP (1.05M shares), PRICE T ROWE ASSOCIATES INC /MD/ (1.04M shares), and MORGAN STANLEY (925K shares).
This table shows the top 3 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.